Evidence map›Paper›PMID 26463716›Full record

ArticleMolecular cancer2015

Butyrate inhibits pro-proliferative miR-92a by diminishing c-Myc-induced miR-17-92a cluster transcription in human colon cancer cells.

Shien Hu, Lan Liu, Eugene B Chang, Jian-Ying Wang, Jean-Pierre Raufman

Open access · goldAbstract read
In one paragraph

Article in Molecular cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 116 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
116citing papers in PubMed, 1 pooled it
4.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

116 citing papers in PubMed, 1 synthesis or guideline pooled it, 179 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review

56 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Shien HuVA Maryland Healthcare System, Department of Medicine, Division of Gastroenterology & Hepatology, and the Marlene and Stewart Greenebaum Cancer Center, University of Maryland School of Medicine, 22 South Greene Street, N3W62, Baltimore, MD, 21201, USA.
Lan LiuVA Maryland Healthcare System, Department of Surgery, University of Maryland School of Medicine, Baltimore, MD, USA.
Eugene B ChangThe Martin Boyer Laboratories, Department of Medicine, University of Chicago School of Medicine, Chicago, IL, USA.
Jian-Ying WangVA Maryland Healthcare System, Department of Surgery, University of Maryland School of Medicine, Baltimore, MD, USA.
Jean-Pierre RaufmanVA Maryland Healthcare System, Department of Medicine, Division of Gastroenterology & Hepatology, and the Marlene and Stewart Greenebaum Cancer Center, University of Maryland School of Medicine, 22 South Greene Street, N3W62, Baltimore, MD, 21201, USA. jraufman@medicine.umaryland.edu.
University of Maryland, Baltimore · USUniversity of Chicago · US

Funding

ULTRASTRUCTURE AND CYTOMORPHOLOGY COREP30DK042086 · NIDDK · UNIVERSITY OF CHICAGO · PI CHANG, EUGENE B · 1990 to 2025
$29.8M
Intestinal Mucosal Growth in Health & Surgical DiseasesR01DK057819 · NIDDK · UNIVERSITY OF MARYLAND BALTIMORE · PI Jian-Ying Wang · 2000 to 2026
$7.4M
Research Training in Gastroenterology and HepatologyT32DK067872 · NIDDK · UNIVERSITY OF MARYLAND BALTIMORE · PI RAUFMAN, JEAN-PIERRE · 2005 to 2024
$7.2M
Surgical Studies of Gut PermeabilityR01DK068491 · NIDDK · UNIVERSITY OF MARYLAND BALTIMORE · PI Jian-Ying Wang · 2004 to 2026
$7.0M
Mucosal Repair in Gut Surgical DisordersR01DK061972 · NIDDK · UNIVERSITY OF MARYLAND BALTIMORE · PI WANG, JIAN-YING · 2002 to 2023
$6.7M
Mutualistic relationship between Hsp25/27 and gut microbes as a major and essential determinant of mucosal healing and microbial fitness following intestinal injuryR01DK047722 · NIDDK · UNIVERSITY OF CHICAGO · PI CHANG, EUGENE B · 1993 to 2020
$4.3M
Cytoprotective Role of Heat Shock Proteins in IBDR37DK047722 · NIDDK · UNIVERSITY OF CHICAGO · PI CHANG, EUGENE B · 2008 to 2017
$3.8M
Dietary fat effects on gut microbes, host immune state and experimental colitisR01DK097268 · NIDDK · UNIVERSITY OF CHICAGO · PI CHANG, EUGENE B · 2012 to 2016
$2.2M
Creating a toolkit to measure in vivo bile acid transportR21DK093406 · NIDDK · UNIVERSITY OF MARYLAND BALTIMORE · PI POLLI, JAMES E, RAUFMAN, JEAN-PIERRE · 2012 to 2013
$404k
REGULATION OF INTESTINAL EPITHELIAL RESTITUTIONI01BX000332 · VA · BALTIMORE VA MEDICAL CENTER · PI Jian-Ying Wang · 2009 to 2026
–
BLRD VA I01 BX000332NIDDK NIH HHS DK067872NIDDK NIH HHS DK093406NIDDK NIH HHS DK42086NIDDK NIH HHS DK47722NIDDK NIH HHS DK57819NIDDK NIH HHS DK61972NIDDK NIH HHS P30 DK042086NIDDK NIH HHS R01 DK047722NIDDK NIH HHS R01 DK057819NIDDK NIH HHS R01 DK061972NIDDK NIH HHS R01 DK068491NIDDK NIH HHS R01 DK097268NIDDK NIH HHS R21 DK093406NIDDK NIH HHS R37 DK047722NIDDK NIH HHS T32 DK067872
6 · The paper itself

Abstract

backgroundCompromised colonic butyrate production resulting from low dietary fiber or altered gut microbiota may promote colon neoplasia. Previous reports indicate these actions are mediated in part by altered levels of miRNAs, including suppressed expression of the oncogenic miR-17-92a cluster. Here, we sought to identify the mechanisms underlying these effects of butyrate in colon cancer.

methodsmiR-92a levels were measured in archived human colon cancer and adjacent normal colon specimens by microarray and quantitative RT-PCR (qPCR). The effects of butyrate and other histone deacetylase inhibitors (suberoylanilide hydroxamic acid (SAHA) and valproic acid) on primary (pri-miR17-92a), precursor and mature miR-92a were analyzed in HCT-116 and HT-29 human colon cancer cells using qPCR. The effects of butyrate, SAHA and valproic acid on protein levels of c-Myc, Drosha and p57 were measured in HCT-116 cells using immunoblotting. Regulation of C13orf25 promoter activity by butyrate was analyzed by luciferase reporter assay using modified pGL3 constructs containing a wild-type or mutated c-Myc binding site. Expression of c-Myc was modulated using siRNA or adenovirus vectors. p57 mRNA and protein were measured before and after transfection with miR-92a-mimic molecules. Following butyrate treatment and miR-92a-mimic transfection, apoptosis was analyzed by TUNEL staining and caspase-3 immunoblotting.

resultsMicroarray, confirmed by qPCR, revealed a seven-fold increase in miR-92a levels in sporadic human colon cancer tissue compared to adjacent normal colon. Treating human colon cancer cells with butyrate reduced the levels of pri-miR17-92a, precursor and mature miR-92a, as well as c-Myc. SAHA and valproic acid had similar effects. Mutation of the c-Myc binding site diminished butyrate's inhibitory effects on C13orf25 promoter activity. Silencing c-Myc expression reduced miR-92a levels. c-Myc over-expression neutralized butyrate-induced attenuation of pri-miR17-92a. Exogenous miR-92a inhibited butyrate-induced p57 expression and reversed the beneficial actions of butyrate on colon cancer cell proliferation and apoptosis.

conclusionsOur findings identify a novel cellular mechanism whereby butyrate inhibits miR-92a transcription by reducing c-Myc, thus augmenting p57 levels. These actions diminish colon cancer cell proliferation and stimulate apoptosis. This newly described regulation of oncogenic miRNA biogenesis expands our understanding of colon cancer cell biology and identifies novel therapeutic targets.

Indexed as

ApoptosisButyratesCell ProliferationColonic NeoplasmsCyclin-Dependent Kinase Inhibitor p57Genes, mycHCT116 CellsHistone Deacetylase InhibitorsHT29 CellsHumansMicroRNAsButyratesCDKN1C protein, humanCyclin-Dependent Kinase Inhibitor p57Histone Deacetylase InhibitorsMicroRNAs

Identifiers

PMID26463716
PMCPMC4604099
OpenAlexW1893584805

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.